Recreated pox virus may yield vaccines and expression systems say scientists

By Flora Southey

- Last updated on GMT


Related tags Smallpox

Researchers at the University of Alberta, Canada say a synthetic version of the extinct horsepox virus could yield more efficient protein expression systems and better vaccines. 

The virus reconstruction project – detailed in a study in the journal Science​ – was prompted in part by an interest in horsepox’s role in the history of vaccine development according to lead researcher David Evans.

“It has been suggested that vaccinia virus (the virus used to vaccinate against smallpox) might have been isolated from cows infected with horsepox virus,”​ he told Biopharma-Reporter.

“This is supported by old experiments from the early 19th century and by modern genome sequencing. We are interested in studying this historical connection between vaccinia and horsepox viruses.”

Horsepox recreation

The researchers used a combination of DNA cloning and a publicly available horsepox genome sequence to reconstruct the virus.

“These were linearized, the appropriate ends added to each of the telomeric fragments, and transfected into cells previously infected with a helper virus.”

“The helper virus catalyses DNA replication and recombination reactions that leads to the assembly of small numbers of infectious particles derived from the transfected DNAs. These ‘reactivated’ viruses are then recovered by plaque purification,”​ he said.


The reconstructed horsepox virus has potential application in the production of vaccines and in biomanufacturing according to Evans.

“We also think that the horsepox virus might be a safer virus vaccine and provide a new platform for the expression of recombinant proteins,”​ he said.

Evans said this could not only enable the development of vaccines against other diseases, but potentially aid the development of viruses that can kill tumours.

Smallpox protection

Despite the eradication of the smallpox virus in 1980, recently interest in the virus shows maintained market demand for vaccines against the smallpox.

Earlier this year​, Canadian firm Tonix developed a live-virus vaccine for smallpox, developed in pre-clinical stages by Evans and Ryan Noyce at the University of Alberta.

As recently as yesterday, Emergent BioSolutions announced​ it will purchase Sanofi’s smallpox vaccine ACAM2000, which was approved by the US Food and Drug Administration in 2007. 

A viral threat?

Evans told us that although animals may still be vulnerable to the horsepox virus, the team is confident that it poses no risk to humans.

“Horsepox virus has not been studied much, but our evidence suggests it behaves like a highly attenuated vaccinia virus. Therefore we treat it as a level 2 agent from a human health perspective.”

“We presume it could still be a hazard to animals, although horsepox as a disease attracted so little notice that it may have gone extinct without anyone really noticing,”​ he said.

However, while the horsepox virus itself may not be a threat, Evans told us the approach used to resurrect it could be applied to any orthopoxcirus virus, including smallpox.

“This would be a hazard to human health unless stringent controls are kept in place to restrict the synthesis of variola virus DNA,”​ he said.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more